Related Experiment Video
Updated: Oct 20, 2025

A Novel Murine Model of Arteriovenous Fistula Failure: The Surgical Procedure in Detail
Published on: February 3, 2016
Interrogating the haemodynamic effects of haemodialysis arteriovenous fistula on cardiac structure and function
Sokratis Stoumpos1,2, Alastair Rankin3,4, Pauline Hall Barrientos5
1Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. sokratis.stoumpos@ggc.scot.nhs.uk.
Insights
Arteriovenous fistula (AVF) creation for haemodialysis significantly increases left ventricular (LV) mass in chronic kidney disease (CKD) patients. This cardiac remodelling is directly proportional to fistula blood flow, highlighting potential cardiovascular risks.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Medical Imaging
Background:
- Arteriovenous fistula (AVF) is the preferred vascular access for maintenance haemodialysis.
- AVF creation may lead to maladaptive cardiovascular remodelling in patients with chronic kidney disease (CKD).
- Understanding the cardiac impact of AVF is crucial for managing CKD patients undergoing haemodialysis.
Purpose of the Study:
- To investigate the effect of AVF creation on cardiac structure and function in CKD patients.
- To assess changes in left ventricular (LV) mass, volumes, ejection fraction, and cardiac output post-AVF creation.
- To determine the relationship between fistula blood flow and cardiac remodelling.
Main Methods:
- Prospective cohort study involving 40 CKD patients undergoing first AVF creation.
- Cardiac magnetic resonance (CMR) imaging performed at baseline and 6 weeks post-AVF creation.
- Ultrasound measurements of fistula blood flow at 6 weeks.
Main Results:
- A significant mean increase of 7.4 g in LV mass was observed 6 weeks after AVF creation (p=0.02).
- Significant increases in LV end-diastolic volumes and cardiac output were noted post-AVF creation.
- Increased LV mass was proportional to fistula blood flow, with higher flows correlating with greater increases.
Conclusions:
- AVF creation for haemodialysis leads to significant increases in LV myocardial mass within weeks.
- The observed cardiac remodelling is directly proportional to fistula blood flow.
- These findings highlight the potential for AVF to induce cardiovascular changes that warrant monitoring in CKD patients.
Abstract:
Arteriovenous fistula (AVF) is the preferred type of vascular access for maintenance haemodialysis but it may contribute to maladaptive cardiovascular remodelling. We studied the effect of AVF creation on cardiac structure and function in patients with chronic kidney disease (CKD). In this prospective cohort study patients with CKD listed for first AVF creation underwent cardiac magnetic resonance (CMR) imaging at baseline and at 6 weeks. All participants had ultrasound measurements of fistula blood flow at 6 weeks. The primary outcome was the change in left ventricular (LV) mass. Secondary outcomes included changes in LV volumes, LV ejection fraction, cardiac output, LV global longitudinal strain and N-terminal-pro B-type natriuretic peptide (NT-proBNP). A total of 55 participants were enrolled, of whom 40 (mean age 59 years) had AVF creation and completed both scans. On the second CMR scan, a mean increase of 7.4 g (95% CI 1.1-13.7, p = 0.02) was observed in LV mass. Significant increases in LV end-diastolic volumes (p = 0.04) and cardiac output (p = 0.02) were also seen after AVF creation. No significant changes were observed in LV end-systolic volumes, LV ejection fraction, NT-proBNP and LV global longitudinal strain. In participants with fistula blood flows ≥ 600 mL/min (n = 22) the mean increase in LV mass was 15.5 g (95% CI 7.3-23.8) compared with a small decrease of 2.5 g (95% CI - 10.6 to 5.6) in participants with blood flows < 600 mL/min (n = 18). Creation of AVF for haemodialysis resulted in a significant increase of LV myocardial mass within weeks after surgery, which was proportional to the fistula flow.
Related Concept Videos
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Hemodialysis III: Nursing Management
Heart Failure Drugs: Diuretics
Heart Failure II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

